![]() Mathew W. MacCumber, MD, PhD, Director of Research - Rush Department of Ophthalmology |
The Rush Department of Ophthalmology is strongly committed to clinical research. The department actively engages in a variety of National Institutes of Health, National Eye Institute, FDA and industry sponsored clinical trials. Being leaders in clinical research is vital to enhancing the educational mission of the department at the resident and fellowship level. The department receives funding from the NIH, the Illinois Society to Prevent Blindness, the Juvenile Diabetes Research Foundation, Alcon Surgical, and Bausch & Lomb. Research activities are coordinated by Mathew W. MacCumber, MD, PhD, the associate chairman for research, Daisy Pacelli, MPH, RN, research manager, and Parth Brahmbhatt, MD, our clinical coordinator. Throughout the training period, support is available for resident and medical student research projects. |
|
Dry AMD
|
Wet AMD
|
|
FUCHS, a double-masked, randomized, placebo-controlled, parallel-group, 12-week study to investigate the safety and efficacy of ripasudil (K-321) eye drops after descemetorhexisin patients with Fuchs endothelial corneal dystrophy This is a multi-center, double-masked, randomized, parallel-group controlled 2-period study after descemetorhexis in patients with Fuchs endothelial corneal dystrophy.
|
|
The objective of the Zoster Eye Disease study (ZEDS) is to determine whether prolonged suppressive oral antiviral treatment with oral Valacyclovir reduces the complications of Herpes Zoster Ophthalmicus (HZO) thereby improving the clinical outcome of this disease. The primary aim of this double masked placebo-controlled multicenter randomized clinical trial will test the hypothesis that suppressive antiviral treatment with oral Valacyclovir for 12 months will reduce the rate of new or worsening disaster corneal disease compared to placebo at the 12 month primary and point.
|
|
ADVISE, Adalimumab vs. conventional Immunosuppression for Uveitis Trial. Treatment of non-infectious, intermediate, posterior, panuvetitis. Adalimumab OR conventional immunosuppressive therapy. Randomized.
|
![]()
|
MERIT, Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (MERIT). This study will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6 month clinic visit. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit. |
Participant(s) | Principal Investigator | Title |
---|---|---|
Sarah Carballo, MD ( PGY4), Grace Alexander |
Pauline T. Merrill, MD |
Monitoring and Predicting Outcomes of Birdshot Chorioretinopathy: A Proposed Prognostic Matrix |
Nabila Sardar, MD (PGY4) | Pauline T. Merrill, MD | Birdshot chorioretinopathy |
Emily Shepherd, MD (PGY3) | Jack A. Cohen, MD | Long term visual and neurodevelopmental outcomes in ROP patients treated with laser photocoagulation versus intravitreal anti-VEGF therapy |
Omar Dajani, MD (PGY6) | John S. Pollack, MD | Impact of Pre-Operative Optical Coherence Tomography (OCT) Abnormalities in Epiretinal Membrane (ERM) Patients on Post-Operative Anatomic and Visual Success: A Retrospective Study |
Naryan Sabherwal, MD | Mathew W. MacCumber, MD, PhD |
Altitude retinopathy case |